INTRODUCTION
============

Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disease characterized by the selective loss of upper and lower motor neurons. A total of 5%--10% of cases of ALS are familial, with the remainder believed to be sporadic.^[@r01]^ The incidence of ALS is uniform across Caucasian populations,^[@r02]^ but the presence of ethnic variation remains unknown.^[@r03]^

The Western Pacific form of ALS, termed ALS and parkinsonism-dementia complex (ALS/PDC), was identified in the 1950s in three distinct geographic isolates: Guam, Western New Guinea, and the Kii Peninsula of Japan.^[@r04]^ The high prevalence and incidence of ALS/PDC has been reported in the Kii Peninsula (eg a prevalence of 47.7 per 100 000 people and an incidence of 9.54 per 100 000 person-years in the Kozagawa focus area of Wakayama prefecture).^[@r05]^ However, little is known about the ALS frequency across Japan as a whole.

In this study, we estimate the prevalence and incidence of ALS in Japan. Furthermore, we compare the incidence between Japan and other countries, and examine geographic variation in the incidence of ALS among prefectures within the country.

METHODS
=======

Specified disease treatment research program in Japan
-----------------------------------------------------

Medical care is ensured for all people in Japan under the universal healthcare system, in which a 30% patient copayment is required for insurance-covered medical care. Some rare and intractable diseases, termed "specified diseases," remain difficult to treat, develop chronically, and constitute a great financial burden for patients and their family because of the high costs associated with long-term care and medicine. The specified disease treatment research program, which started in 1972, subsidizes the patient copayment for insured patients suffering from designated intractable diseases. A patient with ALS can receive that financial support, independent of disease severity.

Case ascertainment of ALS
-------------------------

When a patient is diagnosed with ALS by their doctor, they can apply to their prefectural government for assistance through the specified disease treatment research program, using the initial clinical application form for a new patient or the renewal form for an existing patient. Specialists in neurology serving on the committee on designated intractable diseases in each prefecture review the clinical application form, which is usually completed by a neurologist, based on the El Escorial Criteria (EEC).^[@r06],[@r07]^ As of 2009, there were 8555 neurologists in Japan.^[@r08]^

The criteria for ALS in this program are as follows^[@r09]^:

1.  adult onset, with a steady, progressive course;

2.  the presence of clinical or electrophysiological evidence of lower motor neuron (LMN) degeneration in at least two topographical anatomic regions (brainstem, cervical, thoracic or lumbosacral region), together with clinical evidence of upper motor neuron (UMN) degeneration in at least one region; and

3.  the absence of electrophysiological and pathological evidence of other disease processes that might explain the signs of LMN and/or UMN degeneration and neuroimaging evidence of other disease processes that might explain the observed clinical and electrophysiological signs.

According to the criteria, patients with definite, probable, or possible ALS are included in this program, based on the revised EEC.^[@r07],[@r09]^

Nationwide mail survey on amyotrophic lateral sclerosis
-------------------------------------------------------

We sent a questionnaire on ALS to all 47 prefectural offices on February 11, 2013, requesting the following information:

1.  the number of patients with certified ALS who received financial aid for the treatment of a designated intractable disease in the 2009 fiscal year, classified by the categories (i) new or existing patients, (ii) sex, and (iii) age at which they were certified as a patient with ALS in the specified disease treatment research program (Note: patient's age at the time of diagnosis, application, and certification during the fiscal year is the same in most cases); and

2.  the total number of neurology specialists and the composition of the committee on designated intractable diseases.

The study period was the 2009 fiscal year, from April 2009 to March 2010, the latest fiscal year before occurrence of the Great East Japan Earthquake on March 11, 2011. We chose to examine events prior the earthquake because of the huge impact that it had on the population structure and quantity and quality of medical institutions and personnel in the Tohoku district, the consequences of which persist to date.

This study was approved by the Institutional Review Board of the National Institute of Public Health, Japan (NIPH-TRN\#12009).

Statistical analysis
--------------------

The annual prevalence rate was calculated from the observed number of all patients with ALS certified as eligible for financial aid for the treatment of a designated intractable disease during the 2009 fiscal year, divided by the population insured by national insurance. It was obtained by subtracting the population in receiving public assistance on July 31, 2009, from the total population on October 1, 2009. Overall, the insured population comprised approximately 99% of the total population. To calculate the annual incidence rate, the numerator was the observed number of patients with ALS newly certified as eligible for financial aid for the treatment of a designated intractable disease during the 2009 fiscal year. The rates were also calculated separately for age and sex.

To compare the incidence of ALS among different ethnic groups,^[@r03]^ the rates were age- and sex-adjusted to the 2000 U.S. standard population using the 50- to 79-years age band by the direct method. We calculated 95% confidence intervals (CIs) under the assumption of Poisson distribution. In addition, geographic variation within the country was examined by calculating standardized incidence ratios (SIRs) and 95% CIs for all 47 prefectures using the indirect method under the assumption of Poisson distribution.^[@r10],[@r11]^ SIR with a 95% CI that did not include 1.0 was considered statistically significant.

RESULTS
=======

All 47 prefectural offices returned their responses by June 2013. A special effort was made to achieve a response rate of 100% and confirm the data provided. Of 614 physicians comprising the committees on designated intractable diseases, the number of neurology specialists was 100, with at least 1 neurology specialist in the committee for each of 46 prefectures (unknown for Saga prefecture).

Table [1](#tbl01){ref-type="table"} shows the number of patients with ALS certified as eligible for financial aid for the treatment of a designated intractable disease during the 2009 fiscal year. Of a total of 10 237, including 6 patients younger than 20 years old, 2264 were patients with newly certified ALS.

###### Number of patients with ALS certified as eligible for financial aid for the treatment of a designated intractable disease in Japan from April 2009 to March 2010

  Age^a^      All patients   New patients                        
  ----------- -------------- -------------- ------ ------ ------ -----
  0--4        0              0              0      0      0      0
  5--9        1              1              0      0      0      0
  10--14      2              0              2      0      0      0
  15--19      3              1              2      1      1      0
  20--24      10             8              2      2      2      0
  25--29      19             14             5      2      1      1
  30--34      50             23             27     8      4      4
  35--39      95             58             37     13     7      6
  40--44      226            120            106    41     17     24
  45--49      319            180            139    55     26     29
  50--54      558            326            232    99     54     45
  55--59      1065           663            402    223    143    80
  60--64      1590           955            635    337    217    120
  65--69      1796           1103           693    394    234    160
  70--74      1948           1111           837    450    269    181
  75--59      1408           752            656    360    194    166
  80--84      843            407            436    204    96     108
  85+         304            120            184    75     37     38
  Total       10 237         5842           4395   2264   1302   962
                                                                 
  Regrouped                                                       
  20+         10 231         5840           4391   2263   1301   962

^a^Age at which a patient was certified as eligible for financial aid for the treatment of a designated intractable disease from April 2009 to March 2010 (Note: Patient's age at the time of diagnosis, application and certification during the fiscal year is the same in most cases).

Table [2](#tbl02){ref-type="table"} shows the annual prevalence and incidence rates of patients with ALS aged 20 years or older. The annual crude prevalence was 9.9 (95% CI 9.7--10.1) per 100 000 people, with the highest age- and sex-specific rate of 27.1 (95% CI 26.2--28.0) per 100 000 people evident in the 70- to 79-years age group. The annual crude incidence was 2.2 (95% CI 2.1--2.3) per 100 000 people, with the highest age- and sex-specific rate of 6.5 (95% CI 6.1--7.0) per 100 000 people evident in the 70- to 79-years age group. Greater numbers of males were evident for both prevalence and incidence. To enhance the comparability of incidence rates among people of different ethnicities, incidence rates were standardized for the 50- to 79-years age band using the 2000 U.S. standard population (Table [2](#tbl02){ref-type="table"}). The rate for both sexes combined was 2.3 (95% CI 2.2--2.4) per 100 000 people.

###### Annual prevalence and incidence rates of patients with ALS, aged 20 years or older, certified as eligible for financial aid for the treatment of a designated intractable disease in Japan from April 2009 to March 2010

                        Both     Male          Female   M:F ratio                                                                                     
  --------------------- -------- ------------- -------- ------------ ------ ------------- ------ ------------ ------ ------------ ------ ------------ -----
  [Prevalence]{.ul}                                                                                                                                    
  20--29                29       14 371 936    0.2      0.1--0.3     22     7 366 821     0.3    0.2--0.5     7      7 005 115    0.1    0.0--0.0     3.0
  30--39                145      18 193 826    0.8      0.7--0.9     81     9 241 101     0.9    0.7--1.1     64     8 952 725    0.7    0.6--0.9     1.2
  40--49                545      16 253 995    3.4      3.1--3.6     300    8 187 477     3.7    3.3--4.1     245    8 066 518    3.0    2.7--3.4     1.2
  50--59                1623     16 631 377    9.8      9.3--10.2    989    8 235 051     12.0   11.3--12.8   634    8 396 326    7.6    7.0--8.2     1.6
  60--69                3386     17 419 338    19.4     18.8--20.1   2058   8 393 464     24.5   23.5--25.6   1328   9 025 874    14.7   13.9--15.5   1.7
  70--79                3356     12 393 683    27.1     26.2--28.0   1863   5 576 087     33.4   31.9--35.0   1493   6 816 596    21.9   20.8--23.0   1.5
  80+                   1147     7 736 961     14.8     14.0--15.7   527    2 627 371     20.1   18.4--21.8   620    5 109 590    12.1   11.2--13.1   1.7
                                                                                                                                                      
  Crude                 10 231   103 001 116   9.9      9.7--10.1    5840   49 627 372    11.8   11.5--12.1   4391   53 372 744   8.2    8.0--8.5     1.4
  [Incidence^d^]{.ul}                                                                                                                                  
  20--29                4        14 371 936    0.0      0.0--0.1     3      14 371 936    0.0    0.0--0.1     1      7 005 115    0.0    0.0--0.0     2.9
  30--39                21       18 193 826    0.1      0.1--0.2     11     18 193 826    0.1    0.1--0.2     10     8 952 725    0.1    0.1--0.2     1.1
  40--49                96       16 253 995    0.6      0.5--0.7     43     16 253 995    0.5    0.4--0.7     53     8 066 518    0.7    0.5--0.9     0.8
  50--59                322      16 631 377    1.9      1.7--2.2     197    16 631 377    2.4    2.1--2.8     125    8 396 326    1.5    1.2--1.8     1.6
  60--69                731      17 419 338    4.2      3.9--4.5     451    17 419 338    5.4    4.9--5.9     280    9 025 874    3.1    2.7--3.5     1.7
  70--79                810      12 393 683    6.5      6.1--7.0     463    12 393 683    8.3    7.6--9.1     347    6 816 596    5.1    4.6--5.7     1.6
  80+                   279      7 736 961     3.6      3.2--4.1     133    7 736 961     5.1    4.2--6.0     146    5 109 590    2.9    2.4--3.4     1.8
                                                                                                                                                      
  Crude                 2263     103 001 116   2.2      2.1--2.3     1301   103 001 116   2.6    2.5--2.8     962    53 372 744   1.8    1.7--1.9     1.5
  Age-adjusted^e^                              2.3      2.2--2.4                          4.7    4.4--5.0                         1.7    1.6--1.9     2.8

^a^Age at which a patient was certified as eligible for financial aid for the treatment of a designated intractable disease from April 2009 to March 2010 (Note: Patient's age at the time of diagnosis, application and certification during the fiscal year is the same in most cases).

^b^The population receiving public assistance on July 31, 2009, is subtracted from the total population on October 1, 2009.

^c^per 100 000 people per year.

^d^The numerator was the number of patients with ALS newly certified as eligible for financial aid for the treatment of a designated intractable disease during the study period.

^e^Age-adjusted incidence was standardized to the 2000 U.S. standard population using the 50- to 79-years age band for ethnic comparison.

Table [3](#tbl03){ref-type="table"} shows the observed and expected numbers of patients with newly certified ALS, and SIRs with 95% CIs for each prefecture. Among males, SIRs were significantly high in Okinawa, Nara, Wakayama, and Niigata, and significantly low in Tokyo and Osaka. Among females, SIRs were significantly high in Kumamoto and significantly low in Miyazaki.

###### Observed and expected numbers of patients with ALS newly certified and the standardized incidence ratio by prefecture in Japan from April 2009 to March 2010

  Prefecture   Male (*n* = 1301)   Female (*n* = 962)                                   
  ------------ ------------------- -------------------- ------------------- ---- ------ -------------------
  Hokkaido     67                  57.3                 1.17 (0.91--1.48)   43   44.4   0.97 (0.70--1.30)
  Aomori       16                  14.3                 1.12 (0.64--1.82)   14   11.8   1.19 (0.65--1.99)
  Iwate        16                  14.9                 1.07 (0.61--1.74)   14   11.8   1.19 (0.65--1.99)
  Miyagi       18                  23.2                 0.77 (0.46--1.22)   11   17.5   0.63 (0.31--1.13)
  Akita        12                  12.8                 0.94 (0.48--1.64)   13   10.4   1.25 (0.66--2.13)
  Yamagata     13                  13.4                 0.97 (0.52--1.66)   14   10.3   1.36 (0.74--2.28)
  Fukushima    26                  22.0                 1.18 (0.77--1.73)   9    16.6   0.54 (0.25--1.03)
  Ibaraki      41                  31.0                 1.32 (0.95--1.79)   21   21.7   0.97 (0.60--1.48)
  Tochigi      16                  20.7                 0.77 (0.44--1.26)   9    14.7   0.61 (0.28--1.16)
  Gunma        22                  21.3                 1.03 (0.65--1.56)   10   15.3   0.65 (0.31--1.20)
  Saitama      70                  71.9                 0.97 (0.76--1.23)   46   48.3   0.95 (0.70--1.27)
  Chiba        61                  63.1                 0.97 (0.74--1.24)   47   43.4   1.08 (0.80--1.44)
  Tokyo        97                  122.5                0.79 (0.64--0.97)   78   88.4   0.88 (0.70--1.10)
  Kanagawa     87                  86.1                 1.01 (0.81--1.25)   70   59.9   1.17 (0.91--1.48)
  Niigata      39                  26.5                 1.47 (1.04--2.01)   25   20.1   1.24 (0.80--1.83)
  Toyama       13                  12.1                 1.07 (0.57--1.83)   12   9.4    1.28 (0.66--2.24)
  Ishikawa     13                  12.1                 1.08 (0.57--1.84)   10   9.3    1.08 (0.52--1.99)
  Fukui        10                  8.7                  1.16 (0.55--2.12)   4    6.6    0.61 (0.17--1.56)
  Yamanashi    11                  9.2                  1.20 (0.60--2.14)   4    6.8    0.59 (0.16--1.51)
  Nagano       24                  24.1                 0.99 (0.64--1.48)   20   17.8   1.12 (0.68--1.73)
  Gifu         32                  22.4                 1.43 (0.98--2.02)   18   16.3   1.11 (0.66--1.75)
  Shizuoka     39                  40.5                 0.96 (0.68--1.31)   30   29.3   1.03 (0.69--1.47)
  Aichi        76                  71.3                 1.07 (0.84--1.33)   45   49.7   0.91 (0.66--1.21)
  Mie          22                  19.9                 1.10 (0.69--1.67)   8    14.6   0.55 (0.24--1.08)
  Shiga        19                  13.4                 1.42 (0.86--2.22)   8    9.7    0.83 (0.36--1.63)
  Kyoto        19                  26.4                 0.72 (0.43--1.12)   14   19.9   0.70 (0.39--1.18)
  Osaka        62                  85.7                 0.72 (0.55--0.93)   70   63.5   1.10 (0.86--1.39)
  Hyogo        43                  56.7                 0.76 (0.55--1.02)   47   42.4   1.11 (0.81--1.47)
  Nara         29                  14.8                 1.96 (1.31--2.81)   9    10.9   0.82 (0.38--1.56)
  Wakayama     20                  11.2                 1.79 (1.10--2.77)   9    8.7    1.03 (0.47--1.96)
  Tottori      7                   6.4                  1.09 (0.44--2.25)   3    5.1    0.59 (0.12--1.75)
  Shimane      14                  8.4                  1.66 (0.91--2.78)   7    6.6    1.05 (0.42--2.17)
  Okayama      24                  20.8                 1.15 (0.74--1.72)   14   15.7   0.89 (0.49--1.49)
  Hiroshima    20                  29.7                 0.67 (0.41--1.04)   18   22.4   0.80 (0.48--1.27)
  Yamaguchi    16                  16.5                 0.97 (0.55--1.57)   15   13.1   1.14 (0.64--1.88)
  Tokushima    11                  8.8                  1.25 (0.62--2.24)   4    6.8    0.59 (0.16--1.50)
  Kagawa       6                   11.0                 0.54 (0.20--1.19)   11   8.3    1.32 (0.66--2.36)
  Ehime        10                  15.7                 0.64 (0.31--1.17)   15   12.4   1.21 (0.68--2.00)
  Kochi        8                   8.6                  0.93 (0.40--1.84)   7    6.9    1.01 (0.41--2.09)
  Fukuoka      43                  47.5                 0.90 (0.65--1.22)   46   37.9   1.21 (0.89--1.62)
  Saga         13                  8.7                  1.50 (0.80--2.56)   11   7.0    1.57 (0.78--2.81)
  Nagasaki     10                  15.1                 0.66 (0.31--1.22)   11   12.2   0.90 (0.45--1.61)
  Kumamoto     21                  19.2                 1.09 (0.68--1.67)   24   15.3   1.57 (1.01--2.33)
  Oita         11                  13.1                 0.84 (0.42--1.50)   14   10.3   1.35 (0.74--2.27)
  Miyazaki     15                  12.3                 1.22 (0.68--2.02)   3    9.6    0.31 (0.06--0.92)
  Kagoshima    16                  18.3                 0.87 (0.50--1.42)   16   14.6   1.09 (0.63--1.78)
  Okinawa      23                  11.4                 2.02 (1.28--3.04)   11   8.3    1.32 (0.66--2.36)

DISCUSSION
==========

This is the first report on the prevalence and incidence of ALS in a representative population of Japan. The annual crude prevalence and incidence rates per 100 000 people per year were 9.9 (95% CI 9.7--10.1) and 2.2 (95% CI 2.1--2.3), respectively. The highest prevalence as well as incidence was evident in the 70- to 79-years age group, and the male-female ratio was approximately 1.5.

According to the *Report on Public Health Administration and Services 2009*,^[@r12]^ the number of patients with ALS-awarded certificates of financial aid for the treatment of a designated intractable disease at the end of the 2009 fiscal year was 8492, which is 1745 fewer than the total of 10 237 identified in our study. The certificates must be returned to the governor of the patient's prefecture if they die. This difference almost corresponds to the number of deaths due to ALS between January 1 and December 31, 2009, recorded as 1797 in the country's vital statistics. We therefore believe that the published value in the report, given as 6.7 per 100 000 people, underestimates the annual crude prevalence of ALS, which has a high fatality rate.

How ethnicity influences an individual's risk of developing ALS is of great concern. A systematic review on the effect of ethnic variation on the incidence of ALS, using an incidence rate standardized to the 2000 U.S. standard population, provides some etiologic clues.^[@r03]^ The age- and sex-adjusted incidence rate of our study, 2.3 per 100 000 people per year, was comparable to the rate of 2.0 per 100 000 person-years reported in Hokkaido, Japan.^[@r03],[@r13]^ These incidence rates are much lower than those reported in recent prospective studies: 6.4 in Ireland, 6.2 in Scotland, 5.5 in Italy (Northern), 5.3 in the U.S. (Washington), and 5.0 in Italy (Puglia); as well as in retrospective studies: 6.6 in the U.S. (Minnesota), 6.0 in Sweden, 5.6 in Canada, 5.3 in Norway, 4.6 in Libya, and 4.2 in Denmark.^[@r03]^ In general, a low incidence is believed to be caused by the low occurrence of a disease, poor access to medical care, short life expectancy, and inter-disease competition.^[@r03],[@r14]^ These latter three conditions are unlikely to account for the low incidence of ALS in Japan, which provides ALS patients with subsidized public medicine and whose population has the longest life expectancy in the world. Therefore, if the difference is genuine, genetic or lifestyle factors that protect against ALS may confer a low risk of ALS in the Japanese population.

In addition, we found variation in the incidence of ALS among prefectures in Japan. Although the reason for that variation was unclear, the combined data of familial and sporadic ALS used in this study might reflect in part the geographic variation of genetic and/or environmental factors contributing to the occurrence of ALS. Among males, SIRs were high in Okinawa, in Nara and Wakayama on the Kii Peninsula, and in Niigata. Okinawa is where hereditary motor and sensory neuropathy with proximal dominancy (HMSN-P) was first reported in 1997.^[@r15]^ The clinical features of HMSN-P include adult-onset ALS accompanied by mild sensory disturbance, progressing to bedridden incapacity.^[@r16]^ Although HMSN-P is inherited as an autosomal dominant characteristic, some patients with HMSN-P may have been included in this study. According to recent reports, a high incidence of ALS persisted in males in Wakayama prefecture,^[@r17],[@r18]^ which is consistent with the findings of our study. Although it remains unclear why the SIR is high in Nara, one possible explanation is the immigration of residents with a family history of ALS from two major endemic foci in Wakayama and Mie prefectures to Nara prefecture in the Kii Peninsula. Future research is required to confirm the above hypothesis by comparing patients' place of birth with place of ALS diagnosis, using information obtained from the clinical application form.

Similarly, the reasons underlying the high SIR in Niigata among males are unclear. A previous mortality study reported that deaths among males due to ALS most often occurred throughout Niigata, Gunma, Nagano, and Fukushima prefectures.^[@r19]^ Considering these findings together, we may speculate that some unidentified foci with a high incidence of ALS exist in this region. Conversely, Tokyo and Osaka presented a slightly lower SIR in males, but the statistical significance was modest. For female patients, SIR was high in Kumamoto but low in Miyazaki; the statistical significance was modest. However, the reason for this discrepancy among prefectures was unclear.

The limitations of our present study should be taken into account. One is the case ascertainment of ALS. As described in the methods, however, this is not so serious, considering the following points: (1) ALS was usually diagnosed by neurologists; (2) the number of neurologists was large^[@r08]^; (3) neurologists have generally followed the clinical guidelines based on the EEC since the recommendation of its use by the research committee on ALS of Japan^[@r09]^; and (4) the agreement between judgments by the doctor who diagnosed and filled out the clinical application form and neurology specialists who reviewed it at the committee on designated intractable diseases was quite high.^[@r20]^ The other is potential regional disparity affecting geographic variation in the incidence of ALS (eg number of neurologists and access to specialized medical care). Given the following point, however, the degree of regional disparity is likely to be small: prefectures with higher or lower concentrations of neurology clinics/departments^[@r21]^ were not consistent with those in which the SIRs of ALS were high or low in our present study. Basically, all ALS patients have been guaranteed free medical access thanks to the provision of financial aid from universal medical insurance since 1961, countermeasures against intractable diseases including ALS since 1972, and nursing-care insurance since 2000.

In conclusion, we report here the annual prevalence and incidence of ALS in a representative population of Japan. We identified some prefectures with a high incidence of ALS. However, the incidence of ALS in the Japanese population was much lower than in Caucasian populations of Europe and North America.
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